Boehringer Ingelheim receives East Bay Innovation Award

Boehringer IngelheimBoehringer Ingelheim Fremont Inc. received the East Bay Innovation Award in recognition for its contribution to the East Bay's culture of innovation. Boehringer Ingelheim's Fremont, California site is an arm of its biopharmaceutical division and provides the entire production technology chain from DNA to drug substance. The site delivers services both for Boehringer Ingelheim’s own products and for its contract manufacturing business, called Boehringer Ingelheim BioXcellence™. The facility is a strategic partner, offering tailor-made contract development and manufacturing services to the biopharmaceutical industry.

The East Bay Innovation Award is sponsored jointly by The East Bay Economic Development Alliance and the San Francisco Business Times, and celebrates the cutting-edge businesses that make the East Bay one of the preeminent regions of innovation in the U.S.

"We are very pleased to receive this award that recognizes our achievements in innovation and our contribution to the Bay Area. Our company vision is Value through Innovation and this award is an example of how we provide value, not only to our patients, but also to the East Bay," said Michael Howaldt, Vice President, Biopharmaceuticals Operations USA and Fremont Site Head.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies with net sales of about 14.7 billion Euros in 2012. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

All activities of the biopharmaceutical contract manufacturing are performed within the Boehringer Ingelheim Biopharmaceuticals GmbH, headquartered in Ingelheim, Germany and are represented by its new brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience - the company has brought more than 20 biopharmaceutical products to market. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China).

Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle-transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...